Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanifibranor multiple ascending dose study in healthy volunteers
NCT03866369Phase 1Completed
- Sponsor
- Inventiva
- Start
- Jan 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing Lanifibranor with Placebo (2 arms). Primary endpoints: Number of Adverse events at 15 days, Number of abnormal Vital signs (blood pressure, pulse) and physical exams at 15 days and 2 more. Started Jan 2019; status: completed.
02
Drugs
lanifibranor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03866369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866369.